Medical Device JCAs Launch and Novel Mechanism Approvals

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: medical device JCAs finally launching, baxdrostat's novel mechanism approval, and ISPOR's evidence judgment shift. Let's get into it.

SaraStarting with a milestone nobody saw coming this smoothly – medical device Joint Clinical Assessments beginning in June with approximately five assessments planned for high-risk devices and IVDs. After all the oncology JCA struggles, this feels remarkably organized.

MarcusThe operational challenge is what interests me. Little is known about how national HTA bodies are preparing for implementation. We've seen the capacity constraints with medicines JCAs – now we're adding device assessments with completely different evidence paradigms.

SaraBut that's exactly why this could work better. Device companies aren't starting from scratch here. They've been watching the oncology JCA trainwreck for months. The learning curve should be less steep.

MarcusI disagree. Device evidence is fundamentally different – real-world performance, operator learning curves, institutional variation. The PICO frameworks that barely work for oncology drugs will be completely inadequate for devices. Five assessments sounds modest until you realize each one will expose methodological gaps we haven't even identified yet.

SaraFair point on methodology, but the political momentum matters. This expansion beyond medicines proves the Commission is committed to the regulation working. That creates pressure for pragmatic solutions rather than the perfectionist paralysis we've seen elsewhere.

MarcusMoving to baxdrostat – AstraZeneca's first-in-class aldosterone synthase inhibitor for hypertension. FDA approved it as the first drug providing a new way to lower blood pressure through CYP11B2 enzyme inhibition without affecting cortisol production.

SaraThis is interesting from a market positioning perspective. Treatment-resistant hypertension with diabetes patients facing heightened risks – that's a defined population where existing therapies have clear limitations. The selectivity mechanism minimizing hormonal side effects could drive strong health economic arguments.

MarcusThe evidence base will be crucial though. Novel mechanisms always sound compelling until you model the real-world comparative effectiveness. We've seen this pattern before – breakthrough designation, strong clinical story, then the health economics fall apart when payers dig into the dossier.

SaraBut this is different. Resistant hypertension populations are already on multiple therapies with suboptimal control. The economic bar isn't perfection – it's demonstrating value over current inadequate management. The diabetes comorbidity angle particularly strengthens the economic case given cardiovascular event costs.

MarcusNICE's Biosimilar Taskforce published updates showing NHS England estimates around one billion pounds could be saved over five years by accelerating biosimilar uptake. The taskforce coordinates activity across the system to optimize uptake and reduce market entry barriers.

SaraOne billion over five years sounds impressive until you realize that's spread across the entire NHS formulary. The real question is whether this taskforce approach can actually move uptake numbers or if it's just more coordination theater.

MarcusThe systematic approach is what matters. NICE introduced this collaborative model in 2025 specifically because fragmented local decisions weren't delivering optimal biosimilar adoption. Coordinated evidence assessment and implementation guidance should reduce the barriers that keep better economic options off formularies.

SaraI'm skeptical that coordination solves the fundamental problem. Prescriber inertia, patient concerns, local contracting complexities – these aren't coordination failures, they're structural resistance to change. A taskforce can't eliminate the clinical and commercial friction that makes brand switching difficult regardless of economic advantages.

MarcusFinally, ISPOR's 2026-2027 trends report signals a fundamental shift – the mandate has moved from generating evidence to being judged on our ability to influence decisions under constraint. AI ranks as the top trend, rising from number three, while consequences of missing the mark are described as enterprise-level.

SaraThis captures something important about HEOR maturation. We're past the era where more data automatically meant better decisions. Now it's about strategic evidence that actually moves market access outcomes.

MarcusThe risk is this becomes an excuse for sloppy methodology in service of commercial objectives. When the report talks about influence over constraint, that sounds dangerously close to advocacy rather than evidence synthesis.

SaraEvidence judgment isn't evidence manipulation. It's recognizing that perfect data doesn't exist and decision-makers need frameworks for imperfect information. The AI trend reflects tools that can handle that complexity better than traditional approaches.

MarcusJune brings device JCAs and novel mechanisms testing new economic paradigms.

SaraWhile HEOR evolves toward strategic decision influence over pure generation. The discipline is maturing fast.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.